Who is sponsoring NCT02571790?

NCT02571790 is sponsored by Assistance Publique Hopitaux De Marseille.

What condition does NCT02571790 study?

NCT02571790 studies Generalized Anxiety Disorders.

Is NCT02571790 still recruiting?

NCT02571790 is currently completed. Last updated 26 May 2023.

Last reviewed 2023-05-26 · How we verify

NCT02571790: Relax-TAG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Virtual Reality and Relaxation for the Treatment of Generalized Anxiety Disorders: a Comparative Study With Standard Relaxation

Completed NA Last updated 26 May 2023

What this trial tests

NA trial testing Relaxation optimized virtual reality in Generalized Anxiety Disorders in 58 participants. Completed in 25 May 2023.

Timeline

13 October 2015

Primary endpoint
3 October 2017

25 May 2023

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	58
Start date	13 October 2015
Primary completion	3 October 2017
Estimated completion	25 May 2023
Sites	1 location across France

Drugs / interventions tested

Relaxation optimized virtual reality
Classical relaxation (without Virtual Reality)

Conditions studied

Generalized Anxiety Disorders — all drugs for Generalized Anxiety Disorders →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

Adults 18 to 65, any sex, with Generalized Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose is threefold: Assess the anxiety reduction, the mood positive effect and the rise of quality of life when using methods of relaxation combined with virtual reality with patients suffering from generalized anxiety disorder in comparison of the effect of traditional relaxation therapy. Observe and evaluate the effect of perceived presence in synthetic environments in the virtual experience of relaxation. Evaluate the therapeutic efficacy of stereoscopy during exposure to relaxing virtual environments for the treatment of generalized anxiety disorder. It is a comparative, randomized, two groups study (29 in each group): * Relaxation optimized virtual reality * Classical relaxation (without Virtual Reality). The protocol comprised for each groups 7 relaxing sessions (with or without virtual reality epending on the group). Each session lasted for approximately 30 to 35 minutes, including a 5-minute pause between immersive trials, in order to avoid cyber sickness in the virtual reality group. Expected results: a measurable therapeutic improvement produced by the combination of relaxation and virtual and its additional effect when compared to the traditional treatment. Measurements of variables and therapeutic effects will be carried out with psychometric measures. The creation process of the relaxing virtual environments has already been completed. The virtual environments are ready for use. The apparatus needed and in our possession include: * A laptop for generating virtual environments * A stereoscopic display * Apparatus for physiological measurements

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Virtual Reality and Relaxation for the Treatment of Generalized Anxiety Disorder: A Randomized Comparative Study with Standard Intervention.
Malbos E, Chichery N, Borwell B, Weindel G, et al · · 2025 · cited 2× · PMID 40004880 · DOI 10.3390/jcm14041351

Verify or expand the search:

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02571790 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 26 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02571790.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing